Table 1. Dosimetric analysis of VAPs and VMPs.
| Organ | OARs | Prescription Dose (Gy) | Target | Metric | Auto-plan: mean ± Std. Dev | Manual plan: mean ± Std. Dev | p-value |
|---|---|---|---|---|---|---|---|
| Head and neck | Brain, brainstem, eyes, lenses, optic nerves, cochlea, parotids, optic chiasm, spinal cord, oral cavity and mandible | Three dose levels of 56.0 Gy, 63.0 Gy and 70.0 Gy in 35 fractions using SIB technique |
Plan efficacy | Plan score (%) | 71.4 ± 8.1 | 68.4 ± 6.8 | 0.48 |
| APT (minutes) | 29.5 ± 1.0 | 45.5 ± 13.5 | 0.00* | ||||
| MU-factor (MU/cGy) | 2.9 ± 0.6 | 2.6 ± 0.7 | 0.38 | ||||
| PTV70 | Dmax (%) | 111.4 ± 2.6 | 110.8 ± 3.5 | 0.35 | |||
| D2% | 105.3 ± 1.5 | 106.8 ± 2.3 | 0.05* | ||||
| D98% | 94.1 ± 3.4 | 95.5 ± 2.6 | 0.16 | ||||
| D50% | 101.9 ± 0.4 | 102.3 ± 2.0 | 0.31 | ||||
| HI | 0.11 ± 0.04 | 0.11 ± 0.04 | 0.47 | ||||
| CI | 0.95 ± 0.04 | 0.91 ± 0.12 | 0.17 | ||||
| PTV63 | Dmean (%) | 98.4 ± 1.1 | 97.8 ± 2.0 | 0.18 | |||
| PTV56 | Dmin (%) | 50.6 ± 14.5 | 57.2 ± 14.3 | 0.16 | |||
| Oesophagus | Oesophagus, both lungs, heart and spinal cord | 50.40 Gy in 28 fractions | Plan efficacy | Plan score (%) | 83.8 ± 3.1 | 84.1 ± 6.2 | 0.48 |
| APT (minutes) | 25.5 ± 2.0 | 41.5 ± 12.0 | 0.00* | ||||
| MU-factor (MU/cGy) | 2.8 ± 0.4 | 2.9 ± 0.5 | 0.38 | ||||
| PTV50.4 | Dmax (%) | 110.6 ± 2.2 | 109.0 ± 2.3 | 0.08 | |||
| D2% | 104.9 ± 2.1 | 104.4 ± 1.8 | 0.27 | ||||
| D98% | 95.8 ± 2.4 | 97.6 ± 1.8 | 0.04* | ||||
| D50% | 102.2 ± 2.2 | 101.9 ± 1.8 | 0.37 | ||||
| HI | 0.09 ± 0.02 | 0.07 ± 0.02 | 0.02* | ||||
| CI | 0.91 ± 0.07 | 0.95 ± 0.06 | 0.13 | ||||
| Breast | Chest wall, axillary and supraclavicular nodal areas, contra-lateral breast, both lungs, heart and spinal cord | 40.50 Gy in 15 fractions | Plan efficacy | Plan score (%) | 68.2 ± 7.2 | 74.1 ± 7.3 | 0.34 |
| APT (minutes) | 31.0 ± 1.5 | 44.5 ± 15.0 | 0.00* | ||||
| MU-factor (MU/cGy) | 2.9 ± 0.3 | 3.1 ± 0.5 | 0.40 | ||||
| PTV40.5 | Dmax (%) | 115.7± 3.2 | 113.2± 2.2 | 0.03 | |||
| D2% | 109.8 ± 2.7 | 106.6 ± 1.6 | 0.02 | ||||
| D98% | 91.0 ± 3.5 | 92.9 ± 1.6 | 0.01 | ||||
| D50% | 102.2 ± 4.3 | 101.4 ± 1.1 | 0.18 | ||||
| HI | 0.25 ± 0.11 | 0.14 ± 0.02 | 0.02 | ||||
| CI | 0.90 ± 0.07 | 0.92 ± 0.04 | 0.12 | ||||
| QI = V105/V95 | 0.26 ±0.05 | 0.16±0.09 | 0.18 | ||||
| Prostate | Prostate, seminal vesicles, bladder, rectum, penile bulb, bowel bag, both femoral heads and nodal areas | Two dose levels: 50.4 Gy to the pelvis and 70.0 Gy in 28 fractions prostate and seminal vesicles using SIB technique | Plan efficacy | Plan score (%) | 86.8 ± 5.0 | 83.5 ± 4.2 | 0.28 |
| APT (minutes) | 31.5 ± 1.0 | 44.0 ± 18 | 0.00* | ||||
| MU-factor (MU/cGy) | 3.0 ±0.2 | 2.9 ± 0.12 | 0.32 | ||||
| PTV70 | Dmax (%) | 107.9 ± 1.6 | 107.0 ± 0.9 | 0.05* | |||
| D2% | 103.5 ± 0.9 | 104.5 ± 2.1 | 0.10 | ||||
| D98% | 95.7 ± 0.9 | 97.7 ± 2.6 | 0.02* | ||||
| D50% | 101.7 ± 0.9 | 102.6 ± 2.1 | 0.13 | ||||
| HI | 0.08 ± 0.01 | 0.07 ± 0.02 | 0.09 | ||||
| CI | 0.94 ± 0.05 | 0.96 ± 0.08 | 0.27 | ||||
| PTV50.4 | Dmin (%) | 44.9 ± 7.3 | 58.7 ± 10.9 | 0.01* | |||
| Cervical | Bladder, rectum, bowel bag, both femoral heads and nodal areas | 50.0 in 25 fractions | Plan efficacy | Plan score (%) | 75.1 ± 10.0 | 79.2 ± 12.7 | 0.34 |
| APT (minutes) | 30.0 ± 1.0 | 42.0 ± 15.0 | 0.00* | ||||
| MU-factor (MU/cGy) | 3.2 ± 0.6 | 3.4 ± 0.6 | 0.22 | ||||
| PTV50 | Dmax (%) | 109.2 ± 1.7 | 108.5 ± 1.8 | 0.18 | |||
| D2% | 105.5 ± 1.5 | 105.0 ± 1.8 | 0.24 | ||||
| D98% | 96.2 ± 2.4 | 96.1 ± 3.1 | 0.47 | ||||
| D50% | 102.5 ± 1.9 | 102.1 ± 1.9 | 0.34 | ||||
| HI | 0.09 ± 0.01 | 0.09 ± 0.02 | 0.43 | ||||
| CI | 0.91 ± 0.09 | 0.91 ± 0.09 | 0.46 | ||||
| Rectum | Bladder, bowel bag, both femoral heads and nodal areas | 50.0 in 25 fractions | Plan efficacy | Plan score (%) | 58.1 ± 4.3 | 59.4 ± 4.5 | 0.48 |
| APT (minutes) | 29.5 ± 1.0 | 43.0 ± 16.5 | 0.00* | ||||
| MU-factor (MU/cGy) | 3.4 ± 1.1 | 3.0 ± 0.4 | 0.16 | ||||
| PTV50 | Dmax (%) | 108.9 ± 1.9 | 108.3 ± 4.1 | 0.34 | |||
| D2% | 104.4 ± 0.6 | 104.8 ± 2.3 | 0.27 | ||||
| D98% | 96.0 ± 1.4 | 97.6 ± 1.4 | 0.01 | ||||
| D50% | 101.5 ± 0.1 | 101.8 ± 1.2 | 0.20 | ||||
| HI | 0.08 ± 0.02 | 0.07 ± 0.03 | 0.16 | ||||
| CI | 0.94 ± 0.05 | 0.96 ± 0.04 | 0.19 | ||||
| PTV45 | Dmin (%) | 69.4 ± 10.6 | 75.6 ± 8.2 | 0.07 |
*
=p values < 0.05
(OARs=organs at risk, Dmax=Maximum dose, Dmin=minimum dose, Dmean = mean dose, p=statistical significance, MU=monitor units, PTV=Planning Target Volume, APT=Average planning time, QI=Quality Index factor=V105%/V95%, D2%&D98% are maximum dose covering 2% and 98% of the PTV, HI= Homogeneity Index = D2%-D98%)/D50%, CI=Conformity Index = V98/PTVvol)